company background image
6785

Alar Pharmaceuticals TPEX:6785 Stock Report

Last Price

NT$43.90

Market Cap

NT$2.5b

7D

-8.5%

1Y

-11.7%

Updated

15 May, 2022

Data

Company Financials
6785 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

6785 Stock Overview

Alar Pharmaceuticals Inc. operates as a drug development company.

Alar Pharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Alar Pharmaceuticals
Historical stock prices
Current Share PriceNT$43.90
52 Week HighNT$55.30
52 Week LowNT$42.80
Beta0
1 Month Change-7.19%
3 Month Change-11.85%
1 Year Change-11.67%
3 Year Changen/a
5 Year Changen/a
Change since IPO-2.44%

Recent News & Updates

Jan 13
We're Hopeful That Alar Pharmaceuticals (GTSM:6785) Will Use Its Cash Wisely

We're Hopeful That Alar Pharmaceuticals (GTSM:6785) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

6785TW PharmaceuticalsTW Market
7D-8.5%-4.6%-3.4%
1Y-11.7%3.0%0.7%

Return vs Industry: 6785 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.

Return vs Market: 6785 underperformed the TW Market which returned 0.7% over the past year.

Price Volatility

Is 6785's price volatile compared to industry and market?
6785 volatility
6785 Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6785 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 6785's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201621Yung-Shun Wenhttps://www.alarpharm.com

Alar Pharmaceuticals Inc. operates as a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which primarily include opioid use disorder, chronic pain, and major depressive disorder. The company is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid addiction; and ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression.

Alar Pharmaceuticals Fundamentals Summary

How do Alar Pharmaceuticals's earnings and revenue compare to its market cap?
6785 fundamental statistics
Market CapNT$2.50b
Earnings (TTM)-NT$64.23m
Revenue (TTM)n/a

0.0x

P/S Ratio

-39.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6785 income statement (TTM)
RevenueNT$0
Cost of RevenueNT$0
Gross ProfitNT$0
Other ExpensesNT$64.23m
Earnings-NT$64.23m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.13
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 6785 perform over the long term?

See historical performance and comparison

Valuation

Is Alar Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


4.68x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6785's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6785's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 6785 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 6785 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6785's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6785 is overvalued based on its PB Ratio (4.7x) compared to the TW Pharmaceuticals industry average (2x).


Future Growth

How is Alar Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


50.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alar Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Alar Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-15.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6785 is currently unprofitable.

Growing Profit Margin: 6785 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6785 is unprofitable, and losses have increased over the past 5 years at a rate of 15.3% per year.

Accelerating Growth: Unable to compare 6785's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6785 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).


Return on Equity

High ROE: 6785 has a negative Return on Equity (-12.02%), as it is currently unprofitable.


Financial Health

How is Alar Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6785's short term assets (NT$528.7M) exceed its short term liabilities (NT$4.5M).

Long Term Liabilities: 6785's short term assets (NT$528.7M) exceed its long term liabilities (NT$1.1M).


Debt to Equity History and Analysis

Debt Level: 6785 is debt free.

Reducing Debt: 6785 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6785 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6785 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 6.7% each year


Dividend

What is Alar Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6785's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6785's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6785's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6785's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6785 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Yung-Shun Wen

no data

Tenure

Dr. Yung-Shun Wen, Ph D., is Chief Executive Officer & Director of Alar Pharmaceuticals Inc. He has experiences in the pharmaceutical industry When he was a director of RD department in a well-known pharma...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Alar Pharmaceuticals Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Alar Pharmaceuticals Inc.
  • Ticker: 6785
  • Exchange: TPEX
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$2.502b
  • Shares outstanding: 57.00m
  • Website: https://www.alarpharm.com

Number of Employees


Location

  • Alar Pharmaceuticals Inc.
  • No. 19, Keyuan Road
  • Rm. 312, 3rd Floor
  • Taichung
  • 407
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/12 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.